Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 15, 2015updated 22 Oct 2021 9:06am

Valeant completes $192m acquisition of Synergetics USA

Canada-based Valeant Pharmaceuticals International has completed the acquisition of precision surgical devices supplier Synergetics USA for $192m.

Canada-based Valeant Pharmaceuticals International has completed the acquisition of precision surgical devices supplier Synergetics USA for $192m.

Valeant’s affiliate Blue Subsidiary signed the deal in September and received antitrust clearance from US Federal Trade Commission earlier this month.

Synergetics USA is primarily involved in developing surgical applications for ophthalmology and neurosurgery and its product lines include precision engineered, disposable and reusable devices, as well as procedural kits.

Under the deal, Valeant acquired all outstanding shares of Synergetics’ common stock for $6.50 per share in cash worth $166.2m.

“Synergetics’ products include VersaVIT 2.0 vitrectomy system that allows staff to focus more time on the surgeon and patient.”

In addition, Synergetics is eligible to receive up to $1 per share, totalling $25.6m, if certain sales targets are achieved.

Synergetics’ products include VersaVIT 2.0 vitrectomy system that allows staff to focus more time on the surgeon and patient.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

The company also provides energy modalities such as laser energy, ultrasonic energy radio frequency for electrosurgery, lesion generation, and visible light energy for less invasive surgery.

Its other products include Directional II laser probe, which can remain straight when entering the eye and eliminates the risk of breaking the natural lens, while enabling surgeons to work around the posterior pole during laser treatment.

In this transaction, William Blair & Company acted as the financial advisor and Armstrong Teasdale acted as legal advisor to Synergetics, while Skadden, Arps, Slate, Meagher & Flom acted as legal advisor to Valeant.

Valeant develops and markets pharmaceutical products and medical devices in the areas of dermatology, gastrointestinal disorder, eye health, neurology and branded generics.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU